Welcome to our dedicated page for Aeon Biopharma news (Ticker: AEON), a resource for investors and traders seeking the latest updates and insights on Aeon Biopharma stock.
AEON Biopharma (AEON) is a clinical-stage biopharmaceutical company advancing ABP-450, its proprietary botulinum toxin therapy for neurological disorders. This page serves as the definitive source for verified company announcements, merger updates, and clinical trial developments.
Investors and researchers will find timely updates on FDA trial phases, partnership agreements, and financial disclosures. Our curated collection includes press releases about therapeutic advancements, strategic acquisitions, and peer-reviewed research findings.
All content undergoes strict verification to ensure alignment with regulatory standards and accurate representation of AEON's clinical pipeline. Bookmark this page for direct access to primary source materials about ABP-450's development progress and corporate milestones.
AEON Biopharma (NYSE: AEON), a clinical-stage biopharmaceutical company developing botulinum toxin treatments, has granted 102,880 restricted stock units (RSUs) to newly hired non-executive employees. The RSUs were approved under the AEON 2025 Inducement Incentive Plan, with a grant and vesting commencement date of May 21, 2025. The RSUs will vest over a four-year period, with 25% vesting annually. These awards serve as employment inducements and comply with Section 711 of NYSE American LLC Company Guide.
AEON Biopharma (NYSE: AEON), a clinical-stage biopharmaceutical company developing botulinum toxin complex treatments, has announced its participation in the upcoming Aegis Capital Corp. 2025 Virtual Conference. The company's President and CEO, Rob Bancroft, will deliver a corporate overview presentation on Wednesday, May 21st at 7:00 a.m. PT / 10:00 am ET. AEON's focus is on developing treatments for multiple therapeutic indications using their botulinum toxin complex technology.
AEON Biopharma (NYSE: AEON), a clinical-stage biopharmaceutical company developing botulinum toxin treatments, has received acceptance from NYSE American for its compliance plan. The exchange has granted AEON until August 3, 2026 to meet minimum market capitalization and stockholders' equity requirements under Sections 1003(a)(i), (ii) and (iii) of the NYSE American Company Guide.
During this period, AEON will undergo periodic reviews to assess progress toward compliance goals. If the company fails to regain compliance by the deadline or doesn't show sufficient progress, NYSE American may initiate delisting proceedings.
AEON Biopharma (NYSE: AEON) has announced the approval of inducement awards in connection with Rob Bancroft's appointment as President and Chief Executive Officer. The Company's Compensation Committee has approved two key grants:
1. A non-qualified stock option to purchase 59,034 shares of AEON Class A common stock, with an exercise price matching the closing price on the grant date
2. 177,103 restricted stock units (RSUs) to be granted upon Form S-8 registration filing or employment start date
Both awards will vest over a four-year period, with 25% vesting annually from the employment start date. These grants are being made under AEON's 2025 Employment Inducement Incentive Award Plan and comply with Section 711 of NYSE American Company Guide.
AEON Biopharma (NYSE: AEON) has appointed Rob Bancroft as President and Chief Executive Officer, effective April 29, 2025. Bancroft, who brings over 25 years of leadership experience in life sciences, will also join AEON's Board of Directors. He previously served as General Manager of Therapeutics at Revance Therapeutics and led Smith & Nephew's Biotherapeutics division.
The appointment comes as AEON advances its ABP-450 program through the 351(k) biosimilar regulatory pathway. ABP-450 shares the same 900kDa molecular weight as BOTOX and aims to provide a comparable alternative in the $3B botulinum toxin therapeutics market. The company expects to announce results from its Biosimilar BPD Type 2a FDA meeting in the second half of 2025.
AEON Biopharma (NYSE: AEON) announced a leadership transition as President and CEO Marc Forth steps down effective April 4, 2025, to pursue another opportunity. Forth will remain on the Board of Directors to provide strategic guidance. Chairman Jost Fischer will serve as Interim CEO while the Board searches for a permanent replacement.
The company, focused on developing botulinum toxin complex for therapeutic indications, is progressing with its 351(k) biosimilar regulatory pathway for ABP-450. The company expects to have a Biosimilar BPD Type 2a meeting with FDA in the second half of 2025, with current cash reserves sufficient to support operations through this milestone.
AEON Biopharma (NYSE: AEON) has reported its Q4 and full-year 2024 financial results, highlighting significant progress in its biosimilar development program for ABP-450. The company has initiated analytical studies in Q4 2024 to prepare for a potential Biosimilar Biological Product Development Type 2a meeting with the FDA in H2 2025.
The company is pursuing a 351(k) regulatory pathway using BOTOX as the reference product, which could enable market access for all of BOTOX's current and future therapeutic indications under a single FDA approval. AEON has commenced primary analytical studies for the comparative analytical assessment (CAA).
In January 2025, AEON strengthened its financial position through an underwritten public offering raising $20.0 million in gross proceeds. The company expects these funds, combined with existing cash, to support operations through 2025. Notably, approximately 89% of the Series B warrants from this offering have been exercised.
AEON Biopharma (NYSE: AEON), a clinical-stage biopharmaceutical company developing a botulinum toxin complex through a 351(k) biosimilar pathway, has announced its participation in the upcoming Leerink Global Healthcare Conference. The event will take place from March 10-12, 2025 in Miami, FL.
Marc Forth, the company's President and Chief Executive Officer, will deliver a corporate overview during the conference. Interested parties can arrange one-on-one meetings with management through their Leerink representatives.
AEON Biopharma (NYSE: AEON), a clinical-stage biopharmaceutical company, has announced a 1-for-72 reverse stock split of its common stock, effective February 26, 2025. The decision was approved by the company's Board of Directors following stockholder authorization at a Special Meeting on February 24, 2025, where shareholders approved a split ratio range of 1-for-5 to 1-for-150.
The reverse split aims to increase the selling price of AEON's common stock to maintain compliance with NYSE American requirements. Trading will continue under the symbol 'AEON' but with a new CUSIP number [00791X 209]. Stockholders' ownership percentages will remain unchanged, except for fractional shares, which will be rounded up to the nearest whole share.
FAQ
What is the current stock price of Aeon Biopharma (AEON)?
What is the market cap of Aeon Biopharma (AEON)?
